StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Crestor (rosuvastatin) by Quarter

Crestor (rosuvastatin) — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Crestor (rosuvastatin): $22M in Q2 2026, down 31.2% from a year earlier. That is the lowest of the 23 quarters on record here.

Latest, Q2 2026
22
Period ended Jun 30, 2026
Change on a year earlier
-31.2%
32 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Crestor | 331 | | 4 | | 1 | | 10 | | ( 18 ) | | 299 | | 9 | | 5 | | - | | - | | - | | 22 | | ( 31 ) | | ( 27 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCrestor (rosuvastatin) — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202622-31.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026320.0%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202533-5.7%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025310.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202532-11.1%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202532-5.9%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202435-5.4%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202431-6.1%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202436+2.9%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024340.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202337+8.8%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202333-10.8%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202335-5.4%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202334-17.1%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202234-33.3%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202237-15.9%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up crestor (rosuvastatin)

Cite this data

StockData. (2026). AstraZeneca Crestor (rosuvastatin) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-crestor-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.